Work

Risk-adapted therapy guided by human papillomavirus (HPV) circulating tumor DNA in patients with HPV-positive oropharyngeal cancer (ReACT 1.0).

Year: 2025

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.16_suppl.6009

Authors: Glenn J. Hanna, Tulika R. Gupta, Lorenzo Trippa, Emily Kim, Alexander D. Droznin, Jacqueline Minken, Lauren Gunasti, Eleni M. Rettig, Danielle N Margalit, Roy B. Tishler, Itai Pashtan, Kartik Sehgal, Michael J. Dennis, Rosh K. Sethi, Donald J. Annino, Laura A. Goguen, Jeffrey Guenette, Ravindra Uppaluri, Robert I. Haddad, Jonathan Daniel Schoenfeld

Institutions: Dana-Farber Cancer Institute, Brigham and Women's Hospital, Dana-Farber Brigham Cancer Center, Harvard University

Language: English

Topic: Head and Neck Cancer Studies

Subfield: Otorhinolaryngology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Dana-Farber Cancer Institute

OpenAlex ID: W4410804256

Cites:

Cited by: 5

Related to: 10